Nanotechnology-Based Medical Devices for the Treatment of Chronic Skin Lesions: From Research to the Clinic

被引:32
作者
Ruggeri, Marco [1 ]
Bianchi, Eleonora [1 ]
Rossi, Silvia [1 ]
Vigani, Barbara [1 ]
Bonferoni, Maria Cristina [1 ]
Caramella, Carla [1 ]
Sandri, Giuseppina [1 ]
Ferrari, Franca [1 ]
机构
[1] Univ Pavia, Dept Drug Sci, Viale Taramelli 12, I-27100 Pavia, Italy
基金
欧盟地平线“2020”;
关键词
chronic wounds; nanotechnologies; medical devices; critical quality attributes; biocompatibility; wound models; clinical evaluation; CE marking; EXCISIONAL WOUND MODEL; IN-VIVO EVALUATION; RODENT MODEL; STAPHYLOCOCCUS-AUREUS; ELECTROSPUN COLLAGEN; DRESSING MATERIALS; SENSITIZATION TEST; HEALING ACTIVITY; IRRITATION TEST; CELL-MIGRATION;
D O I
10.3390/pharmaceutics12090815
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic wounds, such as pressure ulcers, diabetic ulcers, venous ulcers and arterial insufficiency ulcers, are lesions that fail to proceed through the normal healing process within a period of 12 weeks. The treatment of skin chronic wounds still represents a great challenge. Wound medical devices (MDs) range from conventional and advanced dressings, up to skin grafts, but none of these are generally recognized as a gold standard. Based on recent developments, this paper reviews nanotechnology-based medical devices intended as skin substitutes. In particular, nanofibrous scaffolds are promising platforms for wound healing, especially due to their similarity to the extracellular matrix (ECM) and their capability to promote cell adhesion and proliferation, and to restore skin integrity, when grafted into the wound site. Nanotechnology-based scaffolds are emphasized here. The discussion will be focused on the definition of critical quality attributes (chemical and physical characterization, stability, particle size, surface properties, release of nanoparticles from MDs, sterility and apyrogenicity), the preclinical evaluation (biocompatibility testing, alternativein vitrotests for irritation and sensitization, wound healing test and animal wound models), the clinical evaluation and the CE (European Conformity) marking of nanotechnology-based MDs.
引用
收藏
页码:1 / 32
页数:32
相关论文
共 189 条
[51]  
European Commission, MEDDEV 2 4 1 REV 9 C
[52]  
European Commission, 2010, GUID CLIN INV GUID M
[53]   Norfloxacin-Loaded Electrospun Scaffolds: Montmorillonite Nanocomposite vs. Free Drug [J].
Faccendini, Angela ;
Ruggeri, Marco ;
Miele, Dalila ;
Rossi, Silvia ;
Bonferoni, Maria Cristina ;
Aguzzi, Carola ;
Grisoli, Pietro ;
Viseras, Cesar ;
Vigani, Barbara ;
Sandri, Giuseppina ;
Ferrari, Franca .
PHARMACEUTICS, 2020, 12 (04)
[54]   Wounding of bioengineered skin: Cellular and molecular aspects after injury [J].
Falanga, V ;
Isaacs, C ;
Paquette, D ;
Downing, G ;
Kouttab, N ;
Butmarc, J ;
Badiavas, E ;
Hardin-Young, J .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (03) :653-660
[55]   Reconstructed skin kits: Reproducibility of cutaneous irritancy testing [J].
Faller, C ;
Bracher, M .
SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY, 2002, 15 :74-91
[56]   Predictive ability of reconstructed human epidermis equivalents for the assessment of skin irritation of cosmetics [J].
Faller, C ;
Bracher, M ;
Dami, N ;
Roguet, R .
TOXICOLOGY IN VITRO, 2002, 16 (05) :557-572
[57]  
FDA, GUID IND CHRON CUT U
[58]  
Fiedler BA, 2017, MANAGING MEDICAL DEVICES WITHIN A REGULATORY FRAMEWORK, P3, DOI 10.1016/B978-0-12-804179-6.00001-0
[59]  
Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2017, DRUG PROD INCL BIOL
[60]  
Frankild S, 2000, ACTA DERM-VENEREOL, V80, P256